-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Financial Toxicity in Hematologic Malignancies

Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Access To Care, Disparities, Diversity, Equity, and Inclusion (DEI), Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.), Socioeconomic Inequities
Thursday, December 16, 2021: 10:00 AM-11:00 AM
Please view the recorded poster presentations prior to attending this virtual session:

Financial toxicity associated with cancer treatment is increasingly recognized as a significant barrier to quality care, with numerous studies demonstrating this association in solid tumors and blood cancers. With the advent of advanced and targeted therapeutics, long-term survival trends for many hematologic malignancies have seen dramatic increases over the last decade. Often, patients and survivors continue to require chronic maintenance therapies or follow-up outpatient visits, leading to financial burden and toxicity over time.

Over the last few years, studies investigating financial toxicity associated with hematologic malignancies have started moving away from descriptive studies to interventional approaches. The purpose of this Poster Walk is to highlight the timely and interesting studies in this area of high importance to patients with hematologic malignancies, with significant implications in the domains of quality of life, quality of care, and health policy.

The following abstracts will be featured in this session:

Financial Toxicity and Associated Patient-Reported Quality of Life in Plasma Cell Disorders, Walker Schmidt

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers, Asher Chanan-Khan

Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies, Heather Reves

Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy, Luca Degli Esposti

How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?, Ron Rabinowicz

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States, Gaurav Goyal

See more of: ASH Poster Walks